Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000

Reuters03-23

Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000

Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%.
FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was RMB 388.8 million, more than doubled.
FY 2025 R&D expenses were RMB 837.8 million, up 0.12%.
Cash and bank balances were RMB 3.3 billion as of Dec. 31, 2025, up 131.55%.
Pipeline updates included a Phase 3 China trial of trastuzumab pamirtecan (DB-1303/BNT323) meeting its primary endpoint of PFS versus T-DM1, and DB-1310 receiving two FDA Fast Track designations in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063552), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621705941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621705941","market":"us","top_or_hot":-1,"title":"Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%.\n        </li>\n<li>\n          FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was RMB 388.8 million, more than doubled.\n        </li>\n<li>\n          FY 2025 R&amp;D expenses were RMB 837.8 million, up 0.12%.\n        </li>\n<li>\n          Cash and bank balances were RMB 3.3 billion as of Dec. 31, 2025, up 131.55%.\n        </li>\n<li>\n          Pipeline updates included a Phase 3 China trial of trastuzumab pamirtecan (DB-1303/BNT323) meeting its primary endpoint of PFS versus T-DM1, and DB-1310 receiving two FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations in 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063552), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDuality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%.\n        </li>\n<li>\n          FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was RMB 388.8 million, more than doubled.\n        </li>\n<li>\n          FY 2025 R&amp;D expenses were RMB 837.8 million, up 0.12%.\n        </li>\n<li>\n          Cash and bank balances were RMB 3.3 billion as of Dec. 31, 2025, up 131.55%.\n        </li>\n<li>\n          Pipeline updates included a Phase 3 China trial of trastuzumab pamirtecan (DB-1303/BNT323) meeting its primary endpoint of PFS versus T-DM1, and DB-1310 receiving two FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations in 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063552), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000500386.USD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLbdzsV0:1","article_id":"2621705941","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621705941","pubTimestamp":1774269495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%.FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was RMB 388.8 million, more than doubled.FY 2025 R&D expenses were RMB 837.8 million, up 0.12%.Cash and bank balances were RMB 3.3 billion as of Dec. 31, 2025, up 131.55%.Pipeline updates included a Phase 3 China trial of trastuzumab pamirtecan  meeting its primary endpoint of PFS versus T-DM1, and DB-1310 receiving two FDA Fast Track designations in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","09606":"映恩生物-B"},"translate_title":"Duality Biotherapeutics 2025财年拥有人应占亏损扩大146.99%至人民币2,594,827,000元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":0.9},"content_text":"Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000\n    \n\n\n          Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%.\n        \n\n          FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was RMB 388.8 million, more than doubled.\n        \n\n          FY 2025 R&D expenses were RMB 837.8 million, up 0.12%.\n        \n\n          Cash and bank balances were RMB 3.3 billion as of Dec. 31, 2025, up 131.55%.\n        \n\n          Pipeline updates included a Phase 3 China trial of trastuzumab pamirtecan (DB-1303/BNT323) meeting its primary endpoint of PFS versus T-DM1, and DB-1310 receiving two FDA Fast Track designations in 2025.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063552), on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621705941","isCrawlerRequest":true}